ORIC’s senior management team has decades of experience in the biotech and pharmaceutical industries, having worked in drug discovery and development at companies such as Merck, Pfizer and Genentech.
Ashraf Hanna, Ph.D., M.D.
Chief Executive Officer
Ashraf Hanna is a biopharmaceutical executive with over 20 years of industry experience. Dr. Hanna was previously the Vice President, Commercial and Medical Affairs Finance at Genentech, and CFO of the Genentech Foundation. He also held leadership roles as VP of Genentech’s Alliance Management and Portfolio Planning groups, and was a member of Genentech’s Commercial Leadership Committee (CLC).
Dr. Hanna previously headed strategy and business development at Tanox, where he successfully partnered their lead drug with Novartis and Genentech, and prior to that was at McKinsey and Company. He has a Ph.D. in Physics from Harvard University and an M.D. from the University of Massachusetts. He studied Physics and Economics at the University of Chicago as an undergraduate.
Valeria Fantin, Ph.D.
Chief Scientific Officer
Dr. Fantin is a biopharmaceutical leader with over a decade of experience in exploratory biology and oncology drug discovery and development. Prior to joining ORIC, she was Vice President of Tumor Cell Biology at Pfizer, responsible for advancing small molecules from target validation to Phase 2 proof-of-concept. Dr. Fantin was also responsible for identifying business development opportunities and leading strategic alliances to broaden Pfizer’s efforts in oncology research.
Prior to joining Pfizer, Dr. Fantin held leadership positions at Agios Pharmaceuticals where she created and advanced an exploratory program of novel cancer metabolism targets into drug discovery, and led the execution of the company’s flagship isocitrate dehydrogenase program. Her earlier career as a researcher included positions focused on epigenetics and kinase drug discovery projects with Merck Research Laboratories and ARIAD Pharmaceuticals. She has contributed to the discovery of numerous compounds currently under clinical evaluation and the development of Zolinza® (vorinostat) and Ibrance® (palbociclib).
Dr. Fantin was awarded the Rising Star Award by the Healthcare Businesswomen’s Association. Dr. Fantin completed postdoctoral training in cancer metabolism and signal transduction at Harvard Medical School and the Howard Hughes Medical Institute, and earned her Ph.D. in molecular and cellular biology from Dartmouth Medical School.
Jennifer Low, Ph.D., M.D.
Acting Chief Medical Officer
Jennifer Low has extensive drug development industry experience, most recently as the Chief Medical Officer and Executive Vice President, Research and Development at Loxo Oncology. Prior to that she was Senior Group Director in oncology development at Genentech, where she oversaw the Erivedge (Hedgehog), Zelboraf (B-raf), Cotellic (Mek), and Tarceva (EGFR) programs. She has co-authored papers appearing in the New England Journal of Medicine and Science and numerous oncology journals.
She received her undergraduate degree from Caltech, her M.D. and Ph.D. degrees from Georgetown, and completed her internal medicine residency at UC Davis, medical oncology fellowship at the National Cancer Institute, and was a Senior Investigator at the Cancer Therapeutics Evaluation Program (CTEP) at NCI and an attending physician in breast cancer at NIH and the National Naval Medical Center in Bethesda.
Vice President, Human Resources
Brian Muma has a broad background in human resources with deep understanding of the biopharmaceutical industry acquired from HR leadership positions across the spectrum from discovery to commercialization. Mr. Muma was previously Vice President of Human Resources for Roche China. Prior to the assignment in China, Brian held senior HR leadership roles at Genentech in R&D, Manufacturing, Commercial Operations and Total Rewards Strategy. Earlier in his career, he was an executive compensation consultant at KPMG and Mercer.
Mr. Muma has completed certification courses in change management, advanced project management and 360 degree feedback as well as advanced training in executive coaching and emotional intelligence. He holds a Bachelors degree in Economics and an MBA from the University of Michigan.
General Counsel, Corporate Secretary, and Senior Director of Business Development
Krys Corbett has more than 20 years of experience in licensing transactions, business development and alliance management, including more than 15 in biopharma.
In previous roles at Genentech and Roche, Ms. Corbett focused on strategic alliances and transactions in Roche Partnering, Genentech Alliance Management and Portfolio Planning, and Genentech Transactional Law. She led transactions for licensing, launch or label expansions of Venclexta®, Lucentis®, Rituxan Hycela®, Erivedge®, and development-stage assets, and provided legal and partnering support for products including Avastin®, Xolair®, Rituxan®, and Cotellic®.
Prior to Genentech/Roche, she was at Wilson Sonsini Goodrich and Rosati, where she advised clients on licensing and M&A transactions. She received her J.D. with honors from Duke University School of Law.
Director of Finance & Operations
Sara Coblin previously worked as Director of Finance at Genentech supporting global CMC operations. Prior to that role, she held other finance positions in R&D, FP&A and Alliance Management supporting partnerships on Ocrevus®, Rituxan®, Tarceva® and many other pipeline programs. Earlier in her career, she worked at Sun Microsystems and Arthur Andersen specializing in business process improvement and ERP systems implementation.
Ms. Coblin is a certified Six Sigma Green Belt. She holds a BA in Economics and Computer Applications from the University of Notre Dame. She also earned an MBA from University of California, Berkeley.